#3868
Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment
Introduction:
Peptide receptor radionuclide therapy using lutetium-177 (PRRT) is thought to be an effective treatment (tx) for patients (pts) with somatostatin-receptor–positive, advanced, progressive neuroendocrine tumors. Real-life experience data has been lacking.
Conference:
Presenting Author:
Authors:
Kavan P,
Rho H,
Probst S,
Abikhzer G,
Rho Y,
Keywords:
neuroendocrine tumor,
lutetium,
PRRT,
efficacy,
safety,
#1918
Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour
Introduction:
Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Kavan P
Authors:
Stavrides-Eid M,
Soo Rho Y,
Barrera I,
Kavan P,
Keywords:
thymic neuroendocrine tumour,
pembrolizumab,
atypical carcinoid,
NETs,
#1240
Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction:
Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference:
12th Annual ENETSConcerence (2015)
Presenting Author:
Kavan P
Authors:
Rho Y,
Gilabert M,
McLean J,
Kavan P,
Keywords:
targeted therapy,
sunitinib,
everolimus,
PNET,
